The American pharmaceutical company Gilead Sciences has agreed to buy the biotechnology company Arcellx for 7.8 billion dollars[1]. Gilead will pay $115 per share in cash and an additional $5 per share if certain sales targets are met[1]. The transaction represents a 68 percent increase over Arcellx's previous share price[3]. The main reason for the acquisition is to gain full control over the drug anito-cel, an experimental CAR-T therapy for patients with multiple myeloma[1]. The US Food and Drug Administration (FDA) should decide on the approval of anito-cell by December 23, 2026[4]. The transaction is expected to close in the second quarter of 2026[1]. Gilead promises that anito-cel could become an essential drug for the treatment of multiple myeloma and that it should be profitable as early as 2028[3].